| Detected | Trial | Change |
|---|---|---|
| 2026-06-02 | NCT06360354 A Study Evaluating Anvumetostat in Combination With Other Therapies in Participants With… |
overall status: "Recruiting" → "Active Not Recruiting" |
| 2026-06-02 | NCT06360354 A Study Evaluating Anvumetostat in Combination With Other Therapies in Participants With… |
Enrollment reduced: 350 -> 120 participants |
| 2026-06-02 | NCT06360354 A Study Evaluating Anvumetostat in Combination With Other Therapies in Participants With… |
date change Primary completion moved earlier: 2027-02-26 -> 2026-10-31 |
| 2026-06-02 | NCT06360354 A Study Evaluating Anvumetostat in Combination With Other Therapies in Participants With… |
date change Completion moved earlier: 2029-02-25 -> 2026-11-30 |
| 2026-05-30 | NCT06881784 Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301) |
Primary endpoint(s) modified |
| 2026-05-30 | NCT06881784 Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301) |
Enrollment increased: 420 -> 590 participants |
| 2026-05-30 | NCT06881784 Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301) |
Trial sites expanded: 129 -> 143 locations |
| 2026-05-30 | NCT07492680 A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants… |
Trial sites expanded: 55 -> 58 locations |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT06881784 | Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301) | NSCLC (Non-small Cell Lung Cancer) | Recruiting |
| NCT07491445 | Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With… | Pancreatic Cancer | Recruiting |
| NCT07252232 | Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal… | Pancreatic Cancer | Recruiting |
| NCT06625320 | Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic… | Pancreatic Cancer | Active, Not Recruiting |
| Phase 2 | |||
| NCT07492680 | A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants… | Solid Tumors | Not Yet Recruiting |
| Phase 1/2 | |||
| NCT06162221 | Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC | Non-Small Cell Lung Cancer, NSCLC | Recruiting |
| NCT06445062 | Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors | Colorectal Cancer | Recruiting |
| NCT06128551 | Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in… | Non-Small Cell Lung Cancer (NSCLC) | Recruiting |
| NCT07397338 | Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors | Advanced Solid Tumors | Recruiting |
| NCT06922591 | Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC &… | PDAC | Recruiting |
| NCT05379985 | Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in… | Non-small Cell Lung Cancer (NSCLC) | Recruiting |
| Phase 1 | |||
| NCT07349537 | Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors | Non-small Cell Lung Cancer (NSCLC) | Recruiting |
| NCT06040541 | Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors | Non-small Cell Lung Cancer (NSCLC) | Recruiting |
| NCT06360354 | A Study Evaluating Anvumetostat in Combination With Other Therapies in Participants With… | Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers | Active, Not Recruiting |